MeiraGTx Holdings (MGTX) Cash from Financing Activities (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Cash from Financing Activities came in at $5.3 million in Q4 2025, up 25.54% YoY from $4.2 million in Q4 2024, and up 2532.88% on a QoQ basis from -$219000.0 in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Cash from Financing Activities (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Cash from Financing Activities data on file, last reported at $5.3 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 25.54% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.3 million (down 77.5% YoY) and the FY2025 annual result came in at $12.3 million, down 77.5% from the prior year.
- Cash from Financing Activities grew to $5.3 million in Q4 2025, from -$219000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $72.9 million in Q3 2022 to a low of -$2.6 million in Q1 2022.
- A 5-year average of $13.0 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 134990.74% in 2022, down 1998.53% in 2022.
- Tracing MGTX's Cash from Financing Activities over 5 years: stood at $1.3 million in 2021, then surged by 1817.61% to $24.8 million in 2022, then increased by 11.59% to $27.7 million in 2023, then slumped by 84.68% to $4.2 million in 2024, then gained by 25.54% to $5.3 million in 2025.
- The last three Cash from Financing Activities figures came in at $5.3 million (Q4 2025), -$219000.0 (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.33 Mn |
| Sep 30, 2025 | -219,000.00 |
| Jun 30, 2025 | 5.45 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 49.96 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | -1.27 Mn |
| Dec 31, 2023 | 27.71 Mn |
| Sep 30, 2023 | -404,000.00 |
| Jun 30, 2023 | 57.95 Mn |
| Mar 31, 2023 | -1.23 Mn |
| Dec 31, 2022 | 24.83 Mn |
| Sep 30, 2022 | 72.95 Mn |
| Mar 31, 2022 | -2.58 Mn |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 54,000.00 |
| Jun 30, 2021 | 223,000.00 |
| Mar 31, 2021 | 136,000.00 |
| Dec 31, 2020 | 69.44 Mn |